文献速递肾小球疾病慢性肾脏病

145例假定良性IgA肾病患者的长期结局

Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

18.6%患者出现eGFR下降≥50%,2.8%进展至终末期肾病,活检时临床或病理变量均无法预测进展。

要点

  • 假定良性IgA肾病患者中18.6%在中位22年后出现eGFR下降≥50%。
  • 2.8%患者进展至终末期肾病,需长期随访评估预后。
  • 活检时临床或病理变量均无法识别进展患者。

核心结论

  • 假定良性IgA肾病患者中18.6%在中位22年后出现进展性疾病,且活检时无法预测。

主要发现

  • 27例(18.6%)出现eGFR下降≥50%,其中4例(2.8%)进展至终末期肾病。
  • 从肾活检至eGFR下降≥50%的平均时间为17.3±5.1年。
  • 42例(29.0%)达到临床缓解。
  • 牛津分类再评估:系膜细胞增生12.3%,内皮细胞增生10.7%,节段性肾小球硬化23.8%,所有活检T0(肾小管萎缩<25%皮质区域)。
  • 活检时记录的临床或组织病理学变量均无法识别进展性疾病患者。

临床怎么用

  • 对假定良性IgA肾病患者需延长随访时间以评估长期预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with immunoglobulin A nephropathy (IgAN) who present with mild to moderate proteinuria and normal renal function are assumed to have excellent short-term renal prognosis, but the long-term prognosis is uncertain. METHODS: Patients were selected from the Norwegian Kidney Biopsy Registry based on the following criteria: diagnostic renal biopsy performed in the period 1988-99, with estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2 and proteinuria <1 g/24 h at the time of biopsy. Patients were invited for a nephrological examination with a review of medical history and investigation of blood pressure, urinary findings and eGFR. RESULTS: A total of 145 patients attended the examination, performed by the first author, after a median of 22 (interquartile range 19-25) years after diagnosis. At the examination, 27 patients (18.6%) had a ≥50% decrease in GFR, of whom 4 (2.8%) had developed end-stage renal disease (ESRD). The mean duration from renal biopsy to ≥ 50% decrease in GFR was 17.3 ± 5.1 years in our cohort. Clinical remission was observed in 42 (29.0%) patients. Renal biopsies were re-examined utilizing the Oxford classification criteria. Mesangial hypercellularity was found in 12.3%, endocapillary proliferation was detected in 10.7% and segmental glomerulosclerosis was observed in 23.8%. All biopsies were scored as T0 (tubular atrophy in < 25% of the cortical area). None of the clinical or histopathological variables recorded at the time of biopsy could identify patients with progressive disease. Cumulative risks of ≥50% decrease in eGFR were 2.1% after 10 years, 4.1% after 15 years, 13.9% after 20 years and 24.7% after 25 years. CONCLUSIONS: We have shown that 18.6% of patients with assumed benign IgAN had progressive disease after a median duration of 22 years and that these patients could not be predicted at the time of biopsy. Our study demonstrates that an extended follow-up period is needed when assessing prognosis in this group of patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Knoop T, Vikse BE, Mwakimonga A, et al. Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy. Nephrol Dial Transplant. 2017. PMID: 29106593. doi:10.1093/ndt/gfx242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。